These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. Palace J; Wingerchuk DM; Fujihara K; Berthele A; Oreja-Guevara C; Kim HJ; Nakashima I; Levy M; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Yountz M; Miller L; Armstrong R; Pittock S; Mult Scler Relat Disord; 2021 Jan; 47():102641. PubMed ID: 33310418 [TBL] [Abstract][Full Text] [Related]
32. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders. Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911 [TBL] [Abstract][Full Text] [Related]